SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sal Milani who wrote (9028)6/3/1998 3:51:00 PM
From: Sal Milani   of 23519
 
To All: From Briefings:

Vivus Inc. (VVUS) 7 1/32 -1 23/32: --UPDATE-- Genesis Merchant Group Securities downgrades male impotence product concern from long-term "buy" to "hold" following the release of several studies on its MUSE impotence product; there does not appear to be overwhelming support among urologists for using MUSE as the preferred form of treatment as efficacy rates range from 10% to 58%.....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News